Retatrutide Research Overview: The Triple Agonist in the Published Literature
Retatrutide (LY3437943) is an unapproved compound under active study in metabolic research. Its mechanism and early evidence are published, but phase 3 results are not, and several questions remain open.
Mechanism: engineered triple agonism
Retatrutide is a 39-amino-acid synthetic peptide built on a GIP backbone, with a C20 fatty-diacid for albumin binding. It activates three receptors at once: GIP, GLP-1 and glucagon. The activity ratio is deliberate: strongest at GIP, moderate at glucagon, and attenuated at GLP-1 relative to the native hormones. The design hypothesis is that GLP-1/GIP suppress intake and improve insulin dynamics, while glucagon adds an energy-expenditure and hepatic fat-oxidation component the other incretins lack.
The published evidence
- Phase 1 established once-weekly pharmacokinetics and tolerability consistent with the incretin class.
- Phase 2 (NEJM, 2023) reported mean weight reduction of ~24% at 48 weeks at the highest dose, without plateau at study end. Adverse events were predominantly gastrointestinal, consistent with class effects.
- Liver-fat sub-study: over 80% of participants with fatty liver at baseline reached normal liver-fat content at the top doses. The result has driven substantial hepatology interest.
- Phase 3 (TRIUMPH program) is ongoing across obesity, diabetes, and obstructive sleep apnea populations; no phase 3 results have published yet.
Open research questions
Current literature focuses on three questions: whether glucagon-driven energy expenditure holds up against compensatory intake in large populations; the heart-rate elevation observed at higher doses; and lean-mass preservation during rapid weight loss. Each remains an active in-vitro and preclinical research area. Receptor-level signaling studies of the triple agonism are still being mapped.
Laboratory notes
Handle as a large lipidated peptide: reconstitute gently in bacteriostatic water, refrigerate at 2–8°C, protect from light, and never shake or freeze the solution (see stability windows). Confirm batch identity by mass spec on the certificate of analysis.
We stock independently tested retatrutide (GLP-3 Reta, 2 x 24mg vials); for comparative work see tirzepatide and the dual-vs-triple comparison. For research use only — not for human or veterinary use.